On June 20, 2025, FibroBiologics, Inc. reported that it converted parts of convertible promissory notes totaling $1.1 million into shares, issuing 2,074,290 common shares at various conversion prices. The remaining principal balance is $5.0 million for the First Note and $3.9 million for the Third Note.